Leaders on the Senate Health, Education, Labor and Pensions Committee have reintroduced a bill to require drugmakers and the Food and Drug Administration to engage in better safety planning before releasing drugs to the public, and to improve the FDAs response to risks identified after a drug is on the market. One of the key provisions of the bill is to establish a publicly available database of clinical trials to help enhance patient enrollment in drug trials, and provide a mechanism to track subsequent progress of trials. In addition, the bill would establish a database to ensure that the results of clinical trials are made public. Sen. Edward Kennedy (D-Mass.), the committees chairman, and ranking member Sen. Mike Enzi (R-Wyo.) hope to get legislation approved before the August recess addressing prescription drug safety, drug user fees and other FDA reauthorizations. Read the release.
Senate bill calls for better drug safety planning
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.